Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

scientific article published on 26 November 2005

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0140-6736(05)67667-2
P3181OpenCitations bibliographic resource ID4440
P698PubMed publication ID16310551
P5875ResearchGate publication ID43472908

P50authorMarja-Riitta TaskinenQ18246437
Markku LaaksoQ28050161
Paul P. GlasziouQ38799353
P2093author name stringScott R
Barter P
Best J
Colman P
d'Emden M
Davis T
Drury P
Ehnholm C
Forder P
Hunt D
Keech A
Kesäniemi YA
Pillai A
Simes RJ
Sullivan D
Whiting M
P2860cites workDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialQ44459441
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialQ44599698
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.Q44798929
Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.Q51621111
Dynamic balanced randomization for clinical trials.Q52386670
WHO clofibrate/cholesterol trial: clarificationsQ67523931
Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabeticsQ69912439
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) StudyQ74507662
Fenofibrate increases creatininemia by increasing metabolic production of creatinineQ78354361
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designQ24569560
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examplesQ24569561
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Q24804541
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]Q24815913
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndromeQ28252498
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsQ29547856
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialQ29622926
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialQ33966645
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).Q34161324
Effect of different antilipidemic agents and diets on mortality: a systematic reviewQ34410711
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseQ34687253
Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetesQ34778046
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemiaQ34820339
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysisQ34974714
Diabetic dyslipidaemia: from basic research to clinical practice.Q35139885
Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study.Q36756284
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart StudyQ41840439
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).Q44128229
P433issue9500
P407language of work or nameEnglishQ1860
P921main subjectcirculatory systemQ11068
type 2 diabetesQ3025883
P304page(s)1849-61
P577publication date2005-11-26
P1433published inThe LancetQ939416
P1476titleEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
P478volume366

Reverse relations

cites work (P2860)
Q43063699"Why is it always the heart which suffers from myocardial infarction?" The "Marburg hypothesis" of the pathogenesis of atherosclerosis
Q374351492009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations
Q380710392011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American
Q283018152013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Q267475592015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Q493962852016 Chinese guidelines for the management of dyslipidemia in adults.
Q481231272017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
Q986136122018 Guidelines for the Management of Dyslipidemia in Korea
Q916110862018 Guidelines for the management of dyslipidemia
Q51743168A Clinical Guide to Combination Lipid-Lowering Therapy.
Q26752487A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Q91362103A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury
Q36700531A Man With Dyslipidemia: To Treat Or Not To Treat?
Q50320306A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Q37672465A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
Q30048180A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Q38106667A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.
Q43167802A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis
Q46973482A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
Q37179792A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies
Q46796677A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet
Q28472432A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials
Q38113494A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs
Q33569334A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants
Q38575410A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Q36011053A review of time courses and predictors of lipid changes with fenofibric acid-statin combination
Q91197948A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure
Q28282265A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
Q40104818ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy
Q37851958AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types
Q43043483Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
Q90573977Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay
Q34291764Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study
Q55401962Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism.
Q37699483Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production
Q36842486Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor
Q43058588Acute renal failure with the combined use of rosuvastatin and fenofibrate
Q38236677Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia
Q36976354Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study).
Q34319662Advances in diabetic retinopathy
Q38088818Advances in our understanding of diabetic retinopathy.
Q37104870Advances in the management of hyperlipidemia-induced atherosclerosis
Q36329908Advances in the treatment of nonalcoholic fatty liver disease
Q37761373Advancing therapy for hypercholesterolemia
Q46822559After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Q46162422Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
Q45420980All at sea: new lipid-lowering drug trials continue to disappoint
Q31101617All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.
Q26798068Alteration of Fatty Acid Oxidation in Tubular Epithelial Cells: From Acute Kidney Injury to Renal Fibrogenesis
Q42711225American College of Endocrinology Pre-Diabetes Consensus Conference: part two.
Q33610712American Diabetes Association indications for statins in diabetes: is there evidence?
Q34608277An ACACB variant implicated in diabetic nephropathy associates with body mass index and gene expression in obese subjects
Q36328050An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
Q35569823An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature
Q48849892An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention.
Q37942705An old friend in a new light: the role of osteocalcin in energy metabolism
Q38032616An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels
Q35050146An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes
Q29999973Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Q34283036Anti-angiogenic treatment strategies for the therapy of endometriosis
Q37139567Antidiabetic action of bezafibrate in a large observational database
Q38296685Antilipidemic Drug Therapy Today and in the Future
Q98153760Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
Q83308503Approach to lipid therapy in the patient with atherosclerotic vascular disease
Q28209964Approaches to prevention of cardiovascular complications and events in diabetes mellitus
Q35042647Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review.
Q91038198Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Q90145015Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Q37281210Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence
Q38383033Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Q37448563Association of Postbreakfast Triglyceride and Visit-to-Visit Annual Variation of Fasting Plasma Glucose with Progression of Diabetic Nephropathy in Patients with Type 2 Diabetes
Q93007473Associations between Triglyceride-Glucose Index and Micro- and Macro-angiopathies in Type 2 Diabetes Mellitus
Q48229572Atherogenic Lipoprotein Subfractions and Carotid Atherosclerosis in Menopausal Women.
Q33776194Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials
Q34139042Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?
Q37119482Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.
Q28200554Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Q28538861Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL
Q37049636Atherosclerosis and cardiovascular risk reduction with PPAR agonists
Q37832648Atherosclerosis in 2010: new therapeutic insights
Q35525108Atherosclerosis in systemic lupus erythematosus
Q34730108Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Q37786650Atherosclerosis regression and high-density lipoproteins
Q37770113Atherosclerosis, diabetes and lipoproteins
Q64901460Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits.
Q45238669Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients
Q46252246Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Q51492959Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Q47801721Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
Q36820247Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update
Q36796520Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise
Q24642372Avosentan reduces albumin excretion in diabetics with macroalbuminuria
Q35809770Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
Q41995332Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy
Q26853571Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes
Q35688214Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Q36014419Best practice in primary care pathology: review 7.
Q84971211Beyond statin therapy: a review of the management of residual risk in diabetes mellitus
Q38100747Beyond statins: lipid management to reduce cardiovascular risk
Q37199135Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism
Q36489752Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
Q34422821Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study
Q57819059Bilirubin, a Cardiometabolic Signaling Molecule
Q51422622Blinded assessment of treatment effects for survival endpoint in an ongoing trial.
Q33908782Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB
Q36049377CYP4A11 variant is associated with high-density lipoprotein cholesterol in women
Q36593266Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
Q47557757Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
Q38176275Cardiometabolic impact of non-statin lipid lowering therapies
Q37161933Cardiometabolic interventions - focus on transcriptional regulators
Q37702722Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease
Q57931390Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!
Q52571293Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus.
Q42398936Cardiovascular disease and glycemic treatment
Q37688153Cardiovascular disease is preventable among women
Q36679594Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents
Q39420208Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Q36419283Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities
Q37803337Cardiovascular drug therapy in the elderly: benefits and challenges
Q36772880Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease
Q37577148Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations
Q37811044Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies.
Q40100018Cardiovascular risk and dyslipidemia among persons living with HIV: a review
Q37877789Cardiovascular risk in diabetic end-stage renal disease patients
Q26998699Challenges in elucidating the genetics of diabetic retinopathy
Q51301866Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
Q37173568Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Q86553722Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD
Q86553726Chapter 5: Referral to specialists and models of care
Q87393564Chapter 5: Triglyceride-lowering treatment in adults
Q44521282Cholesterol goals: moving from numbers to treatment
Q37030666Cholesterol trials and mortality
Q46971473Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region
Q33286262Cholesterol--when is lower better?
Q61799320Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week
Q33590777Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Q33722806Circadian rhythms and metabolic syndrome: from experimental genetics to human disease.
Q64075657Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
Q89585086Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy
Q33900204Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges
Q37011769Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
Q95633714Clinical approach to the inflammatory etiology of cardiovascular diseases
Q38420505Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
Q36379507Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects
Q36675450Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Q35070830Clinician's guide to the updated ABCs of cardiovascular disease prevention
Q53087837Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours.
Q28728567Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy
Q38063295CoQ10 and L-carnitine for statin myalgia?
Q88868163Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Q37842472Combination lipid therapy in type 2 diabetes mellitus
Q37663503Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study
Q35101789Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial
Q34231611Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction
Q37103948Combination therapy in the management of mixed dyslipidaemia
Q37855939Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
Q37857866Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
Q46126670Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment.
Q28659915Common variants associated with plasma triglycerides and risk for coronary artery disease
Q39593365Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea
Q33956562Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care
Q47392228Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
Q39367068Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors
Q37206677Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
Q36831038Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia
Q58102300Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
Q36528535Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087
Q33577611Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Q47236264Computational and experimental investigation of DNA repair protein photolyase interactions with low molecular weight drugs.
Q38232357Congenital lipodystrophies and dyslipidemias
Q34980772Consensus statement on management of dyslipidemia in Indian subjects
Q38815387Coronary Computed Tomography Angiography for Screening in Patients with Diabetes: Can Enhanced Detection of Subclinical Coronary Atherosclerosis Improve Outcome?
Q46914500Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia
Q36911699Coronary heart disease and cardiovascular autonomic neuropathy in the elderly diabetic
Q51930537Correction to the FIELD study report.
Q38186099Critical review of non-statin treatments for dyslipoproteinemia.
Q35942012Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy
Q38124404Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
Q38546242Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
Q38338437Current drug treatment of hyperlipidemia in older adults.
Q33646780Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Q37196514Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Q36970318Current strategies for ischemic stroke prevention: role of multimodal combination therapies
Q36911423Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process
Q37775820Darapladib: an emerging therapy for atherosclerosis
Q41998111Deciphering molecular mechanism underlying hypolipidemic activity of echinocystic Acid
Q90748230Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases
Q38141575Demystifying the management of hypertriglyceridaemia.
Q34014812Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis
Q27654470Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists
Q93160429Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease -
Q34530098Diabetes & coronary heart disease: current perspectives
Q26750905Diabetes Dyslipidemia
Q26782844Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Q36783914Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need
Q42584933Diabetes and lipid lowering: where are we?
Q30528669Diabetes in older adults
Q34308751Diabetes in older adults: a consensus report
Q39427190Diabetes mellitus and stroke: A clinical update
Q37984922Diabetes, hyperglycaemia, and acute ischaemic stroke
Q83474625Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Q33446544Diabetes: managing dyslipidaemia
Q57475590Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
Q37119313Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials
Q81315582Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials
Q37757979Diabetic dyslipidemia: extending the target beyond LDL cholesterol
Q96172012Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
Q34790721Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic
Q34498235Diabetic retinopathy: pathogenesis, clinical grading, management and future developments
Q33302529Diabetic retinopathy: treatment and prevention
Q55109775Diabetische Retinopathie
Q37737551Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Q36964616Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol.
Q35895453Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics
Q39214885Distinct but complementary contributions of PPAR isotypes to energy homeostasis.
Q37972824Do persons with diabetes benefit from combination statin and fibrate therapy?
Q37119260Do statins reduce events in patients with metabolic syndrome?
Q40082318Does IMPROVE-IT prove it?
Q33776187Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Q37355471Does reversal of oxidative stress and inflammation provide vascular protection?
Q37119252Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Q36712986Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
Q46199518Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids
Q36438737Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Q37771014Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs
Q35903126Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Q36718446Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide
Q40017196Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Q26774903Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
Q38773023Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
Q37291520Dyslipidaemia as a predictor of hypertension in middle-aged men.
Q87602479Dyslipidaemia in perspective
Q50180407Dyslipidaemia in the elderly: to treat or not to treat?
Q35029623Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
Q54394383Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia.
Q38777322Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease
Q38508952Dyslipidemia and cardiovascular disease in women
Q37311034Dyslipidemia and cardiovascular risk: the importance of early prevention
Q26851294Dyslipidemia and its therapeutic challenges in renal transplantation
Q36839937Dyslipidemia in type 2 diabetes mellitus
Q46116452Dyslipidemia in type 2 diabetes mellitus
Q38088216Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management
Q33776181Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.
Q38049066Dyslipidemia: management using optimal lipid-lowering therapy
Q22241786ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary
Q38325814Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Q41001502Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics
Q41223740Effect of Fenofibrate Medication on Renal Function
Q35146964Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression
Q90481227Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial
Q90481174Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica
Q91934331Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
Q51385582Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
Q37206183Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Q59796327Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
Q33305306Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Q51745604Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Q59335245Effect of fenofibrate on uric acid level in patients with gout
Q47388747Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers
Q37484551Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
Q33686312Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients.
Q36013120Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.
Q38089207Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development.
Q38856838Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review
Q56558843Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats
Q30364133Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
Q37064893Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats
Q28244205Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Q36295672Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial
Q35498269Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse
Q58384543Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study
Q36005146Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia
Q48209248Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
Q30353176Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?
Q90202860Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis
Q34262967Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
Q83549170Effects of combination lipid therapy in diabetes mellitus
Q33889260Effects of combination lipid therapy in type 2 diabetes mellitus
Q38293501Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function
Q79778566Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Q34282749Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting
Q42586832Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants
Q57274310Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
Q37105236Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Q45535226Effects of fibrates on cardiovascular outcomes
Q33576435Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Q33442332Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice
Q79843492Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus
Q33602077Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy
Q50535809Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study.
Q51470916Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Q36909527Effects of pioglitazone on lipid and lipoprotein metabolism
Q37594830Effects of preventive acupuncture and moxibustion on fat accumulation, blood lipid, and uterus e 2 of menopause rats.
Q35189566Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
Q37578267Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
Q52599940Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Q98613627Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial
Q38382774Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multic
Q37509280Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
Q46973474Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
Q46810258Elevated serum creatinine levels associated with fenofibrate therapy
Q55710149Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid.
Q38263909Emerging drugs for hyperlipidaemia: an update
Q38293506Emerging small molecule drugs
Q38217102Emerging therapeutic approaches to treat dyslipidemia
Q37812007Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure
Q38086841Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy
Q37288105Established and emerging approaches for the management of dyslipidaemia
Q84612643Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Q35987990Estimation of adjusted rate differences using additive negative binomial regression
Q36736169Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management
Q64285261Evaluating All Potential Oral Complications of Diabetes Mellitus
Q24608464Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
Q52721054Evaluation of lipid profile and its relationship with blood pressure in patients with Cushing's disease.
Q83749876Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes
Q34630829Evolution of peroxisome proliferator-activated receptor agonists
Q38058381Examining the safety of PPAR agonists - current trends and future prospects
Q38219487Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia
Q90722135Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Q36087108Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation
Q38011204Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Q36847314Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
Q36522005FIELD study
Q36703114Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease
Q30917948Fall in population-based mortality from coronary heart disease negated in people with diabetes mellitus: data from England
Q44206732Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Q37605212Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis
Q30248492Fenofibrate and Diabetic Retinopathy
Q46909170Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Q80804741Fenofibrate and diabetic retinopathy
Q40777122Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Q37612824Fenofibrate and metabolic syndrome
Q45998863Fenofibrate and risk of minor amputations in diabetes.
Q38088377Fenofibrate and the kidney: an overview.
Q42377473Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model.
Q37331280Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner
Q37297015Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress
Q33305305Fenofibrate for diabetic retinopathy
Q37681585Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study
Q57190536Fenofibrate improves vascular endothelial function and contractility in diabetic mice
Q33912957Fenofibrate in primary biliary cirrhosis: a pilot study.
Q37554863Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial
Q37770249Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Q37238488Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
Q33642616Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway
Q42281309Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases
Q33736139Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
Q41605028Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats
Q83306839Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis
Q30419020Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
Q38118853Fenofibrate-associated nephrotoxicity: a review of current evidence
Q37653029Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
Q28220294Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review
Q33933474Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus
Q95794110Fenofibrate: a review of its use in dyslipidaemia
Q36702091Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
Q37329141Fenofibrate: treatment of hyperlipidemia and beyond
Q37992119Fenofibric acid for hyperlipidemia
Q35221085Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability
Q28284661Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Q90377775Fibrate pharmacogenomics: expanding past the genome
Q37576105Fibrate therapy and renal function
Q36562239Fibrate therapy in patients with metabolic syndrome and diabetes mellitus
Q37771902Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found
Q37704392Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid
Q94454408Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Q36679599Fibrates after the FIELD study: Some answers, more questions
Q42218338Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.
Q35889448Fibrates and cholestasis
Q28287250Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
Q38260501Fibrates and niacin: is there a place for them in clinical practice?
Q21246041Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Q30241199Fibrates for primary prevention of cardiovascular disease events.
Q24186376Fibrates for secondary prevention of cardiovascular disease and stroke
Q24204000Fibrates for secondary prevention of cardiovascular disease and stroke
Q24195161Fibrates for type 2 diabetes mellitus
Q24204016Fibrates for type 2 diabetes mellitus
Q43050781Fibrates in CVD: a step towards personalised medicine
Q36366283Fibrates in combination with statins in the management of dyslipidemia
Q49571281Fibrates in the management of atherogenic dyslipidemia.
Q84960836Fibrates reduce the risk of major cardiovascular and coronary events compared with placebo, but do not affect risk of cardiovascular or all-cause mortality
Q28279732Fibrates, glitazones, and peroxisome proliferator-activated receptors
Q36742410Fibrates: what have we learned in the past 40 years?
Q37368691Fibrates: where are we now?
Q40330590Field of confusion: future prospects for fibrate therapy in cardiovascular disease
Q37196864First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa: High Incidence and Progression of Retinopathy and Relationship to Human Immunodeficiency Virus Infection
Q61451411Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1
Q44874088Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Q36573908Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction
Q34000840Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment
Q28070152Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Q35898200Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.
Q37251490Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
Q93109141HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk
Q30251918HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Q38739884HDL cholesterol: reappraisal of its clinical relevance
Q38195221HDL hypothesis: where do we stand now?
Q38391229HDL particle subpopulations: Focus on biological function
Q38217089HDL: to treat or not to treat?
Q37018213HIV-associated dyslipidaemia: pathogenesis and treatment
Q53088204HRT and breast cancer risk: a realistic perspective.
Q37847616Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential
Q36807491Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction
Q35975150Hepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in Mice
Q43817772Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Q42953260High Density Lipoprotein Turnover is Dependent on Peroxisome Proliferator-Activated Receptor α in Mice
Q28476672High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy
Q37264429High density lipoprotein: a therapeutic target in type 2 diabetes
Q34313937High density lipoproteins-based therapies for cardiovascular disease
Q45947888High dietary methionine plus cholesterol stimulates early atherosclerosis and late fibrous cap development which is associated with a decrease in GRP78 positive plaque cells.
Q83426043High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia
Q34637683High prevalence in Malawi of sight-threatening retinopathy and visual impairment caused by diabetes: identification of population-specific targets for intervention
Q90006079High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk
Q38965138High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.
Q35844499High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
Q37400405High-density lipoprotein cholesterol: current perspective for clinicians
Q37707412High-density lipoproteins and cardiovascular disease: 2010 update
Q36892501Homocysteine and cardiovascular disease: a review of the evidence
Q37424324Homocysteine and lipids: S-adenosyl methionine as a key intermediate
Q36889170How can we prevent cardiovascular disease in diabetes
Q37004718Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
Q37677038Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice
Q36609968Hyperlipidemia as a risk factor for cardiovascular disease
Q34045514Hyperlipidemia medication management in patients admitted for a myocardial infarction
Q37861888Hypertension and lipid management in prediabetic states
Q49894643Hypertension with diabetes mellitus complications.
Q39181612Hypertriglyceridaemia and risk of coronary artery disease
Q92793323Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study
Q60533968Hypertriglyceridemia
Q47180199Hypertriglyceridemia and atherosclerosis
Q88697605Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Q55176268Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care.
Q37058951Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy
Q24672914Hypertriglyceridemia: its etiology, effects and treatment
Q30244825Hypertriglyceridemia: the importance of identifying patients at risk
Q60727742Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals
Q41726958ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy
Q37464513Iatrogenic severe depression of high-density lipoprotein cholesterol
Q47422605Identification and Characterization of Fenofibrate-Induced Liver Injury
Q37682488Identification of Patients With Diabetes Who Benefit Most From a Health Coaching Program in Chronic Disease Management, Sydney, Australia, 2013.
Q33940875Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.
Q35567828Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs
Q36701499Impact of diabetes on cardiovascular disease: an update
Q34901492Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents
Q42943434Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study
Q37704388Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy
Q35777145Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
Q88477468Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins
Q43029247Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?
Q37201658Importance of achieving the composite endpoints in diabetes
Q34620714Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective
Q36018677In vitro antimalarial activity and drug interactions of fenofibric acid
Q37577126In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion
Q38198762Incidence and precipitants of hospitalization for pancreatitis in people with diabetes: the Fremantle Diabetes Study
Q39942361Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Q41214273Incidence and progression of diabetic retinopathy in Sub-Saharan Africa: A five year cohort study.
Q47844045Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Q36721159Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome
Q34541793Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database
Q37701553Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease
Q92859105Individualised screening for diabetic retinopathy: the ISDR study-rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening
Q85895949Inducing effect of clofibric acid on stearoyl-CoA desaturase in intestinal mucosa of rats
Q38786058Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Q38831490Influence of HDL particles on cell-cholesterol efflux under various pathological conditions
Q34149881Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats
Q93049588Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
Q35936964Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.
Q81312274Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose
Q26740443Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders
Q34698887Insulin resistance and atherosclerosis
Q36966063Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.
Q49908591Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.
Q37964753Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
Q39892570Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective
Q30372692Is fenofibrate a reasonable treatment for diabetic microvascular disease?
Q35624965Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study
Q37073546Is raising HDL a futile strategy for atheroprotection?
Q36640581Is the metabolic syndrome a real clinical entity and should it receive drug treatment?
Q35871962Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?
Q46237709Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Q58362346Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
Q55069710Japanese Clinical Practice Guideline for Diabetes 2016.
Q37245464Kidney function and estimated vascular risk in patients with primary dyslipidemia
Q38240747LDL cholesterol: controversies and future therapeutic directions
Q37307992LDL reduction: how low should we go and is it safe?
Q64355400LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study
Q30248925LDL-Cholesterol: Standards of Treatment 2016: A German Perspective
Q35747811LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Q90079595Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Q28579542Leptin induces hypertrophy through activating the peroxisome proliferator‐activated receptor α pathway in cultured neonatal rat cardiomyocytes
Q92150307Life Style Intervention Improves Retinopathy Status-The Finnish Diabetes Prevention Study
Q57182351Linking diabetes and atherosclerosis
Q27024982Lipid abnormalities in kidney disease and management strategies
Q39097856Lipid and other management to improve arterial disease and survival in end stage renal disease
Q35285568Lipid biology of the podocyte--new perspectives offer new opportunities
Q37853015Lipid control in patients with diabetes mellitus
Q84393166Lipid disorders in type 2 diabetes
Q42425149Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits
Q37810593Lipid lowering for secondary prevention of cardiovascular disease in older adults
Q34530349Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
Q38248011Lipid mediators in diabetic nephropathy
Q43058605Lipid-lowering agents and new onset diabetes mellitus
Q87170468Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
Q37576110Lipid-lowering drugs and risk for cancer
Q38699252Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening
Q36573878Lipid-lowering effects of statins: a comparative review
Q38222135Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
Q46809610Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.
Q37619497Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges
Q35232239Lipid-lowering therapy in older persons
Q37084296Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention
Q26827432Lipid-lowering therapy: who can benefit?
Q37900938Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome.
Q53205337Lipids and Diabetic Retinopathy.
Q37961883Lipids and diabetic retinopathy
Q36586503Lipotoxicity
Q39584105Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
Q50893620Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Q36334542Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study
Q40471167Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Q43448661Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20).
Q35650429Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
Q36904436Low-density lipoprotein cholesterol in high-risk asymptomatic individuals
Q57796293Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Q36587615Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients
Q33890208Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
Q35230819Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Q55464963Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment.
Q37750261Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome
Q36902774Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome
Q36865071Management of coronary artery disease in patients with type 2 diabetes mellitus
Q64262692Management of diabetic dyslipidemia: An update
Q79196435Management of diabetic dyslipidemia: doing the right thing
Q62493181Management of diabetic retinopathy
Q33402889Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Q35772115Management of dyslipidaemias
Q37707165Management of dyslipidemia in people with type 2 diabetes mellitus
Q38039980Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Q34068746Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Q36412642Management of extracranial carotid artery disease
Q36646276Management of hypertension and dyslipidemia
Q28219256Management of hypertension in patients with diabetes
Q33935729Management of hypertriglyceridemia in the diabetic patient
Q27009375Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway
Q46714886Management of the metabolic syndrome in cardiovascular disease
Q37385184Managing diabetic dyslipidemia: beyond statin therapy
Q38934909Managing the lipid profile of coronary heart disease patients
Q37012012Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Q33528966Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
Q89811716Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Q38083007Medical management of stable coronary atherosclerosis.
Q38085041Medical strategies to reduce amputation in patients with type 2 diabetes
Q38290764Mendelian randomisation applied to drug development in cardiovascular disease: a review.
Q30407506Mendelian randomization of blood lipids for coronary heart disease
Q36054778Metabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes.
Q36916909Metabolic syndrome management
Q37901053Metabolic syndrome: nature, therapeutic solutions and options
Q36012953Metabolic syndrome: the danger signal in atherosclerosis
Q60961572Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria
Q33877294MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models
Q27026545MicroRNAs as potential therapeutic targets in kidney disease
Q40274682Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes
Q30548231Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study
Q49886209Mitochondrial dysfunction in diabetic kidney disease.
Q47958098Mitochondrial energetics in the kidney
Q26859582Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy
Q33942486Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina
Q26829098Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
Q34594935Molecular Implications of the PPARs in the Diabetic Eye.
Q34099937Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes.
Q37254899Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
Q38843479Monoclonal Antibodies for Lipid Management
Q36366129Mortality rates in trials of subjects with type 2 diabetes
Q36470320Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease
Q43217643Multitherapy for diabetes
Q93563258Multitherapy for diabetes
Q34230175Nanopharmaceuticals (part 1): products on the market
Q28072298New Era of Lipid-Lowering Drugs
Q53401128New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Q90380337New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Q37899907New approaches to the treatment of nephropathy in diabetes
Q37956122New horizons for cholesterol ester transfer protein inhibitors
Q47279052New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Q36540320Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol
Q44004071Niacin: the only vitamin that reduces cardiovascular events
Q36329934No accord for the ACCORD-Lipid trial results
Q33901914Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Q38272551Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
Q37204025Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review
Q100946503Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Q28084156Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council
Q46959415Normalization of metabolic syndrome using fenofibrate, metformin or their combination
Q33751308Novel Pharmacologic Approaches for the Management of Diabetic Retinopathy
Q46030429Novel action of 7-O-galloyl-D-sedoheptulose isolated from Corni Fructus as a hypertriglyceridaemic agent.
Q37990618Novel pathways and therapies in experimental diabetic atherosclerosis
Q34768716Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up
Q60146019Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy
Q38186327Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment
Q38656281Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia
Q30249819Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.
Q34877739Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes
Q37367669Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy
Q38477187One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response
Q38283386Ongoing challenges for pharmacotherapy for dyslipidemia
Q24626884Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk
Q81097348Optimal medical therapy with or without percutaneous coronary intervention for stable coronary disease: the COURAGE Study
Q46494907Optimal treatment of the diabetic patient with multivessel disease
Q53168850Optimizing lipid-lowering therapy in the prevention of coronary heart disease.
Q51718394Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
Q26824004Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Q36561806Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis
Q89207225PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Q38586615PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Q26784482PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Q36444975PPAR Agonists and Cardiovascular Disease in Diabetes
Q54936265PPAR Agonists and Metabolic Syndrome: An Established Role?
Q42214835PPAR Medicines and Human Disease: The ABCs of It All.
Q37996437PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Q50773167PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Q45974432PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Q39200940PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Q37616202PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.
Q61648721PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice
Q35000567PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans
Q36154953PPARalpha in atherosclerosis and inflammation
Q30390555PPARalpha: an emerging therapeutic target in diabetic microvascular damage.
Q36889164PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Q92128876PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Q37362740PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Q42820928PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway
Q41911186PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
Q36536316PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Q36807697Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism.
Q38757894Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment
Q37861885Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus.
Q37340704Patient self-report of prior laser treatment reliably indicates presence of severe diabetic retinopathy
Q37413789Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life
Q92892621Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Q37640263Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Q36366326Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia
Q48189776Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease.
Q36261125Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
Q37992593Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
Q37583596Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?
Q39982196Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein
Q37861955Peroxisome proliferator-activated receptors and atherosclerosis.
Q26866784Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review
Q36845108Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.
Q37412297Peroxisome proliferator-activated receptors in diabetic nephropathy
Q35636191Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease
Q37016305Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease
Q37012017Pharmacogenetics of the PPAR genes and cardiovascular disease
Q42623314Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus
Q34628781Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
Q39320400Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
Q36944008Pharmacologic therapeutics for cardiac reperfusion injury
Q37357337Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus
Q90445373Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Q39015072Pharmacological management of diabetic dyslipidemia
Q37842120Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Q38262435Pharmacological treatment and therapeutic perspectives of metabolic syndrome.
Q38130111Pharmacotherapies for lipid modification: beyond the statins
Q37801374Pharmacotherapy of dyslipidemias in the adult population
Q84764505Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go?
Q57500367Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Q34347027Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
Q57463626Plasmapheresis for hypertriglyceridemia: The association between blood viscosity and triglyceride clearance rate
Q37472064Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment
Q42164828Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
Q37549374PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.
Q37639159Postprandial Hyperlipidemia and Remnant Lipoproteins
Q92888992Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes
Q37964751Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review
Q39440767Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Q47875819Practical aspects in the management of statin-associated muscle symptoms (SAMS).
Q38014975Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia
Q33956714Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study
Q36648858Preventing microalbuminuria in patients with type 2 diabetes
Q35013431Prevention and early detection of vascular complications of diabetes
Q55154739Prevention and management of statin adverse effects: A practical approach for pharmacists.
Q22241916Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association
Q36734315Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions?
Q35622601Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study
Q29619982Progress and challenges in translating the biology of atherosclerosis
Q38839105Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.
Q36536280Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
Q37494202Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review
Q36383197Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
Q47868740Proteomics landscape of radiation-induced cardiovascular disease: somewhere over the paradigm
Q38365322ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS.
Q34382652Racial/ethnic differences in dyslipidemia patterns
Q34271942Raising HDL cholesterol in women.
Q58123970Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial
Q36920620Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy
Q33578422Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Q37892300Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus
Q36410620Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.
Q43201242Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus
Q93609057References
Q93609219References
Q38160494Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
Q33572259Regulation of oxidative stress and cardioprotection in diabetes mellitus
Q36345240Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study).
Q36372677Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Q38997960Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study
Q83602703Relevance of the serum apolipoprotein ratio to diabetic retinopathy
Q57956749Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes
Q33359672Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved
Q46981976Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Q36968971Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges
Q26996039Residual macrovascular risk in 2013: what have we learned?
Q37622065Residual microvascular risk in diabetes: unmet needs and future directions
Q39638361Retinal vascular calibre as a predictor of incidence and progression of diabetic retinopathy
Q53165465Retinal vascular calibre, geometry and progression of diabetic retinopathy in type 2 diabetes mellitus.
Q37565692Retinal vascular changes and diabetic retinopathy
Q36823777Retinal vascular signs in diabetes and hypertension--review
Q37702862Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy
Q30419512Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants
Q38239205Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies
Q38430793Role for combination therapy in diabetic dyslipidemia
Q39817316Role of PPARα and Its Agonist in Renal Diseases.
Q38546383Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
Q34976710Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes
Q53093527Role of fibrate drugs in the prevention of diabetic foot.
Q37811855Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Q27000731Role of lipotoxicity in endothelial dysfunction
Q36802569Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia
Q36889865Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus
Q37973966Role of the PPAR-α agonist fenofibrate in severe pediatric burn
Q48141985Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.
Q37741779Role of triglyceride-rich lipoproteins in diabetic nephropathy
Q46363801Rosiglitazone and pioglitazone in the treatment of diabetes mellitus
Q41753267Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis
Q34481529Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
Q38541832Safety considerations with fenofibrate/simvastatin combination.
Q38352759Saroglitazar for the treatment of dyslipidemia in diabetic patients
Q38041209Second line options for hyperlipidemia management after cardiac transplantation.
Q48632120Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Q46466078Secondary prevention after myocardial infarction
Q37229876Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Q37056590Secondary stroke prevention: inside the vessels and beyond
Q36580568Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis
Q38110581Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
Q56972590Serum LDL cholesterol levels and new onset of arterial hypertension: an 8-year follow-up
Q91875427Serum lipid management in patients with type 1 and type 2 diabetes: a hospital-based cohort study
Q45922693Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids.
Q35111638Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants
Q36446970Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Q36415856Should all patients with metabolic syndrome be treated with statins?
Q36422727Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence
Q42915854Should niacin be the preferred drug to add to a statin?
Q42945058Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?
Q37346390Should we start all patients with diabetic retinopathy on fenofibrates?
Q46199534Should we treat all primary prevention patients with statins?
Q36823774Silent myocardial ischemia screening in patients with diabetes mellitus
Q39435430Simulating lifetime outcomes associated with complications for people with type 1 diabetes.
Q39743309Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes
Q33562131Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Q36642327Small, dense low-density-lipoproteins and the metabolic syndrome.
Q24541529Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
Q89537341Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Q37036416Standards of medical care in diabetes--2009.
Q33554238Standards of medical care in diabetes--2010.
Q34425055Standards of medical care in diabetes--2011.
Q24632533Standards of medical care in diabetes--2012
Q29620309Standards of medical care in diabetes--2013
Q38881156Statin combination therapy and cardiovascular risk reduction
Q48145497Statin drug interactions and related adverse reactions: an update
Q37351347Statin use and lower extremity amputation risk in nonelderly diabetic patients
Q28083004Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Q36900804Statins and C-reactive protein levels
Q38020453Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes
Q37757988Strategies for the development of new PPAR agonists in diabetes
Q84121717Strategies to achieve target LDL levels
Q36124203Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
Q38160901Summarizing the FIELD study: lessons from a 'negative' trial
Q36602779Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis
Q36712679Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
Q35067111Systemic medical management of diabetic retinopathy
Q38904497Targeting ApoC-III to Reduce Coronary Disease Risk
Q33809886Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs
Q38846534Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm
Q38431166Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance
Q35084845Targeting metabolic disturbance in the diabetic heart
Q90242473Targeting metabolic dysregulation for fibrosis therapy
Q38880569Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy
Q37242352Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice
Q34695851Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
Q104500079Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
Q36783686The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses
Q35871965The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Q33390186The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein
Q51321256The Combination of Elevated Triglycerides and Abnormal Fasting Glucose Increases Risk of Cerebral Infarction in Patients With Mild to Moderate Hypercholesterolemia: A Post Hoc Analysis of the MEGA Study.
Q60955111The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Q94475289The FIELD study
Q83158057The FIELD study
Q57475802The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Q36478394The Functions of PPARs in Aging and Longevity
Q41348534The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor
Q64923599The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.
Q36445381The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects
Q37311116The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Q89534430The Rise and Fall "ing" of the HDL Hypothesis
Q42292833The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus.
Q30234550The Role of Emerging Risk Factors in Cardiovascular Outcomes
Q52722809The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α) in Kidney Disease.
Q98177451The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction
Q42773416The causes and consequences of low levels of high density lipoproteins in patients with diabetes
Q35295065The chylomicron: relationship to atherosclerosis
Q37230691The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
Q37404473The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate
Q35332645The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
Q37699675The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy.
Q34615937The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Q46973476The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes
Q37978209The emerging role of HDL in glucose metabolism
Q34042836The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies
Q90197758The impact of artificial intelligence in the diagnosis and management of glaucoma
Q36323280The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
Q46548609The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles
Q36921672The importance of free fatty acids in the development of Type 2 diabetes.
Q37132923The importance of treating cardiometabolic risk factors in patients with type 2 diabetes
Q37000746The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes
Q51372447The influence of risk factors for metabolic syndrome on vascular complications.
Q33569142The metabolic syndrome
Q37362674The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Q38118163The need for combination drug therapies in patients with complex dyslipidemia
Q38267131The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know
Q30380628The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Q37079828The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Q85718887The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells
Q86057048The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
Q37997004The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes
Q80139743The role of PPAR-alpha agonists in the prevention of CVD in diabetes
Q36744879The role of Spectral Domain Optical Coherence Tomography in monitoring uncontrolled hypertensive type 2 diabetic patients
Q46952308The role of fenofibrate in clinical practice
Q24651324The role of genetics in susceptibility to diabetic retinopathy
Q34730815The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer
Q36936918The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes
Q35060328The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe
Q33776214The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review.
Q36892498The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Q36781520The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective
Q36982574The treatment of dyslipidemia--what's left in the pipeline?
Q95492629The use of fibric Acid derivatives in cardiovascular prevention
Q35078274Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment
Q35180084Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice
Q37981725Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Q37825945Therapies for diabetic dyslipidaemia
Q37464743Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Q37144139Therapy and clinical trials: management of diabetic dyslipidemia
Q28219591Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines
Q46108030Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice
Q37367666Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Q57112903Towards more specific treatment for diabetic dyslipidemia
Q41811073Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.
Q38201721Treating low high-density lipoprotein cholesterol: what is the evidence?
Q36815978Treating the metabolic syndrome.
Q35460295Treatment approaches for diabetes and dyslipidemia
Q49689988Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
Q33887783Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Q36079624Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status
Q27026114Treatment of dyslipidemia
Q34499472Treatment of dyslipidemia in patients with type 2 diabetes
Q36975868Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors
Q36560981Treatment of hypertriglyceridemia
Q34099851Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087
Q92649743Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
Q37015549Triglyceride and cardiovascular risk: A critical appraisal
Q57127377Triglyceride to HDL-cholesterol ratio as an independent risk factor for the poor development of coronary collateral circulation in elderly patients with ST-segment elevation myocardial infarction and acute total occlusion
Q36151033Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients.
Q58550770Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Q34181381Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Q26745946Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Q33610637Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Q37244736Triglycerides and risk for coronary artery disease
Q91926577Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
Q38553671Tubular atrophy in the pathogenesis of chronic kidney disease progression
Q34023548Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Q36539101Type 2 diabetes and cardiovascular risk in the UK south Asian community.
Q37153041Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors
Q37104865Type 2 diabetes mellitus: prevention of macrovascular complications.
Q26798326Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
Q27687851Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.
Q37504704Update on strategies to increase HDL quantity and function
Q37019924Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Q36766923Update on the use of fibrates: focus on bezafibrate
Q24678615Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Q43490546Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes
Q28548389Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases
Q36623164Use of chronic disease management programs for diabetes: in Alberta's primary care networks.
Q90338365Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
Q34428524Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials
Q35903762Use of fibrates in the United States and Canada
Q26765234Use of fibrates in the metabolic syndrome: A review
Q97682129Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes
Q89312828Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options
Q57269550Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Q30244247Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy
Q36894180Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
Q46809067Waist-to-hip ratio correlates with homocysteine levels in male patients with coronary artery disease
Q39388920We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture
Q100669091Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
Q37812296What combination therapy with a statin, if any, would you recommend?
Q37961240What matters in ADVANCE and ADVANCE-ON.
Q39528844What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?
Q93702607What's new in the other general journals
Q35945237Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
Q38253965Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
Q37923968Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Q42707587World Congress on the insulin resistance syndrome, 2009: cellular mechanisms of insulin resistance
Q42767776World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1
Q43768587Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.
Q91975849Xuezhitong capsule, an extract of Allium macrostemon Bunge, exhibits reverse cholesterol transport and accompanies high-density lipoprotein levels to protect against hyperlipidemia in ApoE-/- mice
Q42642151Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study
Q52813315[Clinical importance of HDL cholesterol].
Q84952346[Diabetic nephropathy]
Q87437305[Lipid therapy for patients with coronary heart disease and diabetes. Current state and perspectives]
Q85725390[Lipids: diagnosis and therapy in type 2 diabetes]
Q88025019[Part I. Fibrates in primary and secondary prevention]
Q88025020[Part II. Combination statin plus fibrate regimens (free and fixed)]
Q88025022[Part III. Clinical control of fenofibrate therapy]
Q39245270cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis
Q38559352α-Lipoic acid as a triglyceride-lowering nutraceutical

Search more.